drugset / Trial / NCT01680198

Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)

NCT01680198 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

The primary aim of this study was to test the hypothesis that Paricalcitol, an active form of vitamin D, improved endothelial function in stage 3-4 chronic kidney disease (CKD) patients. A secondary aim of this trial was to study the relationship between endothelial function and plasma/serum and genetic biomarkers of bone mineral disorders in CKD (BMD-CKD) and renin angiotensin-aldosteron system (RAS) (angiotensin II and plasma renin activity).

Timeline

Start
2011-06
Primary completion
2012-08
Completion
2012-08

Outcome

Met primary endpoint

paper the between-group difference in flow-mediated dilation changes (the primary end point, 1.8%; 95% confidence interval, 0.3-3.1%) was significant (P=0.016) PMID 25259743 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Paricalcitol Other / unclassified 2 ug —